Analyst consensus rating
Atara Biotherapeutics Analyst Rating: none
Direct answer
Atara Biotherapeutics's consensus rating is none.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $13.67.
Forecast evidence checked October 18, 2026.
Get free Atara Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $9.18
- Average price target
- $13.67
- High price target
- $18.00
- Low price target
- $10.00
- Low target gap
- +8.9%
- Target upside
- +48.9%
- High target gap
- +96.1%
- Target range width
- 87.1%
- Consensus rating
- none
- Analysts
- 3
- Evidence date
- October 18, 2026
- Valid through
- October 25, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Atara Biotherapeutics?
Atara Biotherapeutics has a verified none consensus. The same dataset has an average price target of $13.67.
How far are Atara Biotherapeutics's low and high targets from the recorded price?
The low target implies +8.9%, while the high target implies +96.1%.
How many analysts are included in Atara Biotherapeutics's consensus?
The verified consensus includes 3 analysts.
How is Atara Biotherapeutics's target upside or downside calculated?
The average target of $13.67 is divided by the recorded price of $9.18, then one is subtracted to produce +48.9%. This does not guarantee a future return.
When was Atara Biotherapeutics's analyst forecast verified?
The data was verified on 2026-10-18. The dataset is valid through 2026-10-25.